ImmuCell Corporation (ICCC)
5.54
0.04 (0.73%)
At close: Apr 21, 2025, 3:59 PM
ImmuCell Revenue Breakdown
| Period Ending | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
|---|---|---|---|
| FirstDefenseProductLineMember Revenue | 5.4M | 5.03M | 4.47M |
| FirstDefenseProductLineMember Revenue Growth | +7.35% | +12.53% | n/a |
| OtherAnimalHealthMember Revenue | 40.59K | 116.75K | 68.86K |
| OtherAnimalHealthMember Revenue Growth | -65.23% | +69.53% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2021 |
|---|---|
| Otherstatesmember Revenue | 2.62M |
| Otherstatesmember Revenue Growth | n/a |
| United States Revenue | 16.62M |
| United States Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 844.04M | 1.59M | 1.33M | 1.2M | 817.49K | 1.25M | 1.45M | 1.58M | 1.19M | 1.19M | 1.27M | 1.33M | 1.1M | 858.71K | 945.75K | 1.08M | 850.9K | 887.88K | 1.06M | 1.11M | 896.43K | 976K | 1.03M | 1.06M | 891.31K | 918.43K | 954.96K | 891K | 832.43K | 799.65K | 894.11K | 845.6K | 846.44K | 837.96K | 756.15K | 864.93K | 683.31K | 644.83K | 700.21K |
| Selling, General, and Administrative Revenue Growth | +53098.65% | +19.04% | +11.54% | +46.18% | -34.54% | -13.66% | -8.26% | +32.16% | +0.46% | -6.81% | -3.86% | +20.48% | +28.11% | -9.20% | -12.83% | +27.51% | -4.16% | -16.62% | -3.90% | +23.60% | -8.15% | -4.85% | -3.14% | +18.81% | -2.95% | -3.83% | +7.18% | +7.04% | +4.10% | -10.56% | +5.74% | -0.10% | +1.01% | +10.82% | -12.58% | +26.58% | +5.97% | -7.91% | n/a |
| Research and Development Revenue | 786.14M | 1.03M | 1.26M | 1.07M | 1.12M | 1.1M | 1.11M | 1.05M | 1.27M | 1.14M | 1.04M | 1.09M | 1.05M | 1M | 1.03M | 1.17M | 1.12M | 1.09M | 974.43K | 972K | 984.73K | 820K | 910.37K | 1.26M | 908.79K | 761.89K | 582.93K | 734K | 585.83K | 387.01K | 339.62K | 253.74K | 307.72K | 380.43K | 302.44K | 331.14K | 301.75K | 271.76K | 330.67K |
| Research and Development Revenue Growth | +76186.70% | -18.38% | +18.44% | -4.69% | +1.72% | -0.98% | +5.80% | -17.36% | +11.52% | +9.93% | -4.99% | +4.09% | +4.74% | -3.00% | -11.87% | +4.17% | +3.36% | +11.51% | +0.25% | -1.29% | +20.09% | -9.93% | -27.92% | +38.98% | +19.28% | +30.70% | -20.58% | +25.29% | +51.38% | +13.95% | +33.85% | -17.54% | -19.11% | +25.79% | -8.67% | +9.74% | +11.03% | -17.81% | n/a |
| Sales and Marketing Revenue | 844.04M | 984.96K | 800.92K | 671.51K | 817.49K | 719.79K | 879.43K | 3.26M | 1.19M | 659.24K | 811.5K | 2.62M | 656.42K | 436.98K | 520.6K | 1.08M | 459.12K | 465.52K | 582.9K | 1.11M | 497.65K | 976K | 607.1K | 1.06M | 494.7K | 475.23K | 531.9K | 891K | 446.73K | 400.45K | 514.48K | 466.3K | 483.71K | 462.31K | 419K | 519.97K | 381.74K | 316.29K | 388.9K |
| Sales and Marketing Revenue Growth | +85593.59% | +22.98% | +19.27% | -17.86% | +13.57% | -18.15% | -72.99% | +172.97% | +80.97% | -18.76% | -68.98% | +298.53% | +50.22% | -16.06% | -52.02% | +136.32% | -1.38% | -20.14% | -47.39% | +122.64% | -49.01% | +60.76% | -42.67% | +114.07% | +4.10% | -10.66% | -40.30% | +99.45% | +11.56% | -22.16% | +10.33% | -3.60% | +4.63% | +10.34% | -19.42% | +36.21% | +20.69% | -18.67% | n/a |